KEGG   DRUG: PembrolizumabHelp
Entry
D10574                      Drug                                   

Name
Pembrolizumab (USAN);
Pembrolizumab (genetical recombination) (JAN);
Keytruda (TN)
Product
Formula
C6504H10004N1716O2036S46
Exact mass
146195.918
Mol weight
146286.2902
Sequence
(Heavy chain)
QVQLVQSGVE VKKPGASVKV SCKASGYTFT NYYMYWVRQA PGQGLEWMGG INPSNGGTNF
NEKFKNRVTL TTDSSTTTAY MELKSLQFDD TAVYYCARRD YRFDMGFDYW GQGTTVTVSS
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG
NVFSCSVMHE ALHNHYTQKS LSLSLGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASKGVS TSGYSYLHWY QQKPGQAPRL LIYLASYLES
GVPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQHSRDLPL TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(dimer; disulfide bridges: H22-H96, H134-L218, H147-H203, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'134-L'218, H'147-H'203, H'261-H'321, H'367-H'425, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01XC18
Product: D10574<JP/US>
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  Disease
Melanoma [DS:H00038]
Non-small cell lung cancer [DS:H00014]
Head and neck squamous cell carcinoma [DS:H00040]
Hodgkin lymphoma [DS:H00007]
Primary mediastinal large B-cell lymphoma
Urothelial carcinoma [DS:H00022]
Colorectal cancer (microsatellite instability-high) [DS:H00020]
Gastric cancer [DS:H00018]
Cervical cancer [DS:H00030]
Comment
Monoclonal antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules (CAMs)
hsa04660  T cell receptor signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC18 Pembrolizumab
      D10574  Pembrolizumab (USAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10574  Pembrolizumab (USAN); Pembrolizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D10574  Pembrolizumab (USAN) <JP/US>
Antineoplastics [br08340.html]
 D10574
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10574
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10574
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10574
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10574
Pharmacogenomic biomarkers [br08341.html]
 Companion diagnostics
  D10574
BRITE hierarchy
Other DBs
CAS: 1374853-91-4
PubChem: 254741536
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system